



truscreen
a world without
cervical cancer

NZX Announcement

26 November 2020

OPENING OF PUBLIC OFFER AND PUBLICATION OF RESEARCH REPORT

As previously announced to the market on 9 November 2020, cervical cancer screening technology company, TruScreen Group Limited (NZX: TRU)(TruScreen or the Company) intends to undertake a capital raising initiative, by way of a public offer, to raise up to NZD\$2 million (“Offer”) in conjunction with TruScreen’s application for the dual listing of its shares on the Australian Securities Exchange (ASX).

The Offer opens today the 26 November 2020 and applications can be made through the online application portal at <https://www.truscreenshareoffer.co.nz/>. A copy of the registered Product Disclosure Statement in support of the Offer is available on the online application portal.

The Offer will close on 18 December 2020 (“Closing Date”).¹

An application has been made to the ASX for TruScreen to be admitted to the Official List of ASX as an ASX Foreign Exempt Listing and for quotation of the new shares to be offered in Australia on the ASX.

If TruScreen is admitted to the official list of ASX, then those Australian based investors in the Offer will have their Shares quoted on the ASX.

The Offer is conditional upon the ASX approving the admission of TruScreen to the Official List of the ASX as an ASX Foreign Exempt Listing and for the quotation of the new shares issued to Australian investors on the ASX on or before that Closing Date (as that date may be varied from time to time). In the event that this condition is not satisfied, then the Offer will not proceed, and all application moneys received by the Company will be refunded to investors in full and without deduction within 5 business days.

An issuer sponsored Research Report on TruScreen prepared by leading biotech analyst Stuart Roberts of Pitt Street Research Pty Limited was published by Pitt Street Research on 23 November 2020. A copy of the report is available on the Company’s website at <https://bit.ly/3nQG6qt>

-ENDS-

For more information, visit www.truscreen.com or contact:

Victoria Potarina
Chief Executive Officer
victoriapotarina@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

¹ The Board of TruScreen has the discretion to extend the Closing Date if it considers it appropriate.



About TruScreen:

TruScreen cervical cancer screening device offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world.

TruScreen's real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with conventional Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructure. As such, TruScreen's target market is low and middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen's cervical cancer screening device is CE-marked and certified for use throughout Europe and NMPA (formerly CFDA) approved for sale in China. The global market potential for TruScreen is significant.